Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance
Date:8/7/2009

on of pipeline inventories compared to the prior year period, which were offset, in part, by higher sales-related deductions. The increase in filled prescriptions primarily relates to DORYX 150 mg, which we launched in the third quarter of 2008 and to which we have dedicated significant promotional efforts, including our recently launched customer loyalty card program. DORYX 150 mg accounted for 76% of new DORYX prescriptions and 72% of total DORYX prescriptions in the quarter ended June 30, 2009. Increased utilization of the customer loyalty card for DORYX 150 mg drove the increase in sales-related deductions in the quarter. Net sales of TACLONEX decreased $2.3 million, or 5.9%, to $36.5 million in the quarter ended June 30, 2009, compared to $38.8 million in the prior year quarter. The decrease in TACLONEX net sales is primarily due to a 5.7% decrease in filled prescriptions, as well as higher sales-related deductions, offset in part, by the impact of higher average sales prices. Net sales of DOVONEX increased by $0.4 million, or 1.4%, in the quarter ended June 30, 2009, compared with the prior year quarter. The increase in net sales of DOVONEX was due to higher average sales prices and a reduction in sales-related deductions, which more than offset a 24.6% decline in filled prescriptions as compared to the prior year quarter.

Net sales of our hormone therapy products increased $3.9 million, or 9.1%, in the quarter ended June 30, 2009, compared with the prior year quarter. Net sales of ESTRACE Cream increased $7.0 million, or 33.1%, in the quarter ended June 30, 2009, compared to the prior year quarter due to increased demand and higher average selling prices. We began promotional efforts for ESTRACE Cream in early 2009 resulting in an increase in filled prescriptions of 21.2% in the quarter ended June 30, 2009 compared with the prior year quarter. Net sales of FEMHRT decreased $3.3 million, or 19.9%, in the quarter ended June 30, 2009 compared
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
4. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference
6. Warner Chilcott Announces 2008 Financial Guidance
7. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
10. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
11. Warner Chilcott Announces Settlement of Securities Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... breeding grounds for microbes -- don,t worry, it,s a ... years, not all microbes are bad. Many active enzymes ... beneficial to humans as an important part of our ... , Candida albicans , an opportunistic yeast pathogen ... doesn,t damage our healthy personal ecosystem. However, when our ...
(Date:9/18/2014)... effect of guidelines recommending that elderly men should not ... at best," according to a new study led by ... a research letter online in JAMA Internal Medicine ... antigen to test for prostate cancer., "We found ... routine screening of elderly men in particular has been ...
(Date:9/18/2014)... York (PRWEB) September 18, 2014 ... to mount in U.S. courts, Bernstein Liebhard LLP ... that the U.S. Food & Drug Administration (FDA) ... that, if implemented, could greatly reduce their use. ... and Urologic Drug Advisory Committee, and the Drug ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Teens and young adults ... a job that provides them with greater responsibility and ... new study. "We found that having a mentor ... the study,s lead author, Steve McDonald, an associate professor ... a university news release. In conducting the ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4Health News: Mentors May Steer Young People Toward More Rewarding Careers 2
... The University of Houston Center for Drug and Social Policy ... the National Institutes of Health to study the long-term consequences ... will be awarded over the next four years. , ... years ago with 160 gang members in west San Antonio," ...
... Tips and Products to Pamper Tired TootsiesBETHESDA, Md., Feb. 12 ... decadent pampering for countless men and women. While the old ... stomach" may still hold true, another body part is gaining ... American Podiatric Medical Association (APMA) survey revealed 84 percent of ...
... Wildcatter Ranch, warriors to utilize natural surroundings to ... journey to heal-JACKSONVILLE, Fla., Feb. 12 Wounded ... that they will host 16 wounded warriors as ... post traumatic stress disorder (PTSD). Project Odyssey ...
... with special health care needs often do not get ... of a recent study by researchers at Wake Forest ... with private insurance have more unmet respite care needs ... families or caregivers who need respite care the most ...
... its kind Global,Consumer Study is here! Never before ... trends in 15 countries. ISPA, working with Research,International, ... Italy, Japan, Russia, Singapore, Spain, Thailand, UK and USA,and ... why people,spa in the 2008 Global Consumer Study. ...
... a key role in the prevention and treatment of ... Endothelial cells line the blood vessels and are critical ... , Researchers at the Centenary Institute have discovered ... cells. , Professor Jenny Gamble, Head of ...
Cached Medicine News:Health News:Gang researchers at UH examine health, consequences of long-term gang 2Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 2Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 3Health News:Wounded Warrior Project's Project Odyssey Aims to Teach Coping Skills for Combating Post-Traumatic Stress in Wounded Warriors 2Health News:Wounded Warrior Project's Project Odyssey Aims to Teach Coping Skills for Combating Post-Traumatic Stress in Wounded Warriors 3Health News:Caregivers not receiving the help they need, study shows 2Health News:Caregivers not receiving the help they need, study shows 3Health News:Worldwide, Stress is the No.1 Reason People Spa 2Health News:Deciphering the body's healing secrets 2
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014 /PRNewswire/ ... today announced that the U.S. Food and Drug ... patient enrollment and dosing of PEGPH20 in SWOG,s ... is designed to evaluate Halozyme,s investigational drug PEGPH20 ... FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic ...
(Date:9/18/2014)... and MELBOURNE, Australia , Sept. ... Biopharma today announced the appointments of Dr. Ashraf ... D.V.M ., M.S., to its Board of Directors. Dr. ... Affairs Finance at Genentech and Chief Financial Officer for ... as Vice President and Global Head of Business Development ...
(Date:9/18/2014)... SYDNEY , Sept. 18, 2014 Australian ... an important US trial of its MiStat™ prostate cancer ... Administration (FDA) regulatory approval upon completion. Minomic,s ... identifying the presence of a proprietary biomarker known as ... surface of prostate cancer cells. Researchers ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... , SUNNYVALE, Calif. , Feb 11 ... second fiscal quarter ended December 31, 2009 . , Upon ... ended December 31, 2009 , the company began recognizing revenue under ... April 2009 . Total revenue recognized under GAAP in our most ...
... Mesa Laboratories, Inc. (Nasdaq: MLAB ) today reported sales ... December 31, 2009 . , Highlights: , ... Nine month cash flow provided by operations exceeded $4,882,000 ... six month period over the prior six months. , ...
Cached Medicine Technology:Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 7Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 8Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 9Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 10Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 11Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 12Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 13Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 14Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 15Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 16Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 17Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 18Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 19Mesa Labs Reports Quarterly Sales and Earnings 2Mesa Labs Reports Quarterly Sales and Earnings 3Mesa Labs Reports Quarterly Sales and Earnings 4Mesa Labs Reports Quarterly Sales and Earnings 5Mesa Labs Reports Quarterly Sales and Earnings 6
... is designed to easily couple with ... coupling eliminates clumsy time consuming delays. ... well. Dorniers patented isocentric locating arm ... simple using the Dornier Relax+ table, ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
Medicine Products: